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Iron oxide-silica nanoparticles (IOSi-NPs) were prepared from a mixture of ferrous chloride tetrahydrate and ferric chloride
hexahydrate dropped into a silica xerogel composite. he structure and morphology of the synthesized maghemite nanoparticles
into the silica xerogel were analysed by X-ray difraction measurements, scanning electron microscopy equipped with an energy
dispersive X-ray spectrometer, and transmission electronmicroscopy.he results of the EDAXanalysis indicated that the embedded
particles were iron oxide nanoparticles. he particle size of IOSi-NPs calculated from the XRD analysis was estimated at around
12.5 nm.he average size deduced from the particle size distribution is 13.7± 0.6 nm,which is in good agreement with XRD analysis.
he biocompatibility of IOSi-NPs was assessed by cell viability and cytoskeleton analysis. Histopathology analysis was performed
ater 24 hours and 7 days, respectively, from the intratracheal instillation of a solution containing 0.5, 2.5, or 5mg/kg IOSi-NPs.he
pathologicalmicrographs of lungs derived from rats collected ater the intratracheal instillationwith a solution containing 0.5mg/kg
and 2.5mg/kg IOSi-NPs show that the lung has preserved the architecture of the control specimen with no signiicant diferences.
However, even at concentrations of 5mg/kg, the efect of IOSi-NPS on the lungs was markedly reduced at 7 days posttreatment.
1. Introduction
In recent years, an increasing interest has been registered for
developing the ield of nanotechnology. Due to the outstand-
ing physicochemical properties that nanoparticles exhibit,
the number of applications involving these nanomaterials is
increasing continuously. Nowadays, nanoparticles can be
found in toothpastes, sunscreens, or food products [1, 2].he
unique chemical, physical, optical [3, 4], electronic [3, 5], and
magnetic [3, 6] properties show that nanoparticles could be
used in biotechnology and biomedicine. he size of these
nanoparticles facilitates their use in engineering of surfaces
and in creating functional nanostructures [3]. Among the
many types of nanoparticles, superparamagnetic iron oxide
nanoparticles (SPIONs) have been already used for several in
vivo applications, showing promising results. hey were used
as contrast enhancement in magnetic resonance imaging [7–
9], for tissue repair [7, 10, 11], for drug delivery in tumour
therapy [7, 12, 13], for stem cell tracking [7, 14], or as heat
mediators in hyperthermia treatments [15]. In order to be
used for these types of applications, the nanoparticles bio-
compatibility could be increased by adding a silica shell. Due
to the biocompatible properties, silica is less likely to degrade
in a biological environment [16, 17].
Cancer is a major health problem worldwide, being res-
ponsible for one in four deaths in the United States, accord-
ing to the American Cancer Society [18]. In this context,
researchers have tried to ind new innovative ways of admin-
istering the treatment more eiciently. One of the major pro-
blems that arise during the targeted administration of drugs,
most commonly used for cancer treatments, is the nonspeci-
icity of the drug towards the pathological site [3]. hus, a
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large dose of medicine is required in order for the treatment
to be efective and the required local concentration to be
achieved.he result consisted of the fact that besides the dam-
aged cells, surrounding healthy cells could be also afected.
herefore, to overcome this impediment, researchers have
focused their attention on developing techniques of magnetic
targeting using superparamagnetic nanoparticles.hey could
be used as drug carriers, being guided by an external mag-
netic ield, thus insuring an efective treatment [3, 19]. Wang
et al. showed that the iron oxide nanoparticles coated with
silica can be targeted to a speciic objective via the antibody-
antigen recognition by conjugation of antibodies to the outer
silica surface [20]. Coating the iron oxide nanoparticles with
various polymers such as silica, dextran, PEG, and HSA can
prevent their uptake by organs. According to previous studies
[21], the silica layer on the surface of iron oxide nanoparticles
increases biocompatibility and stability against chemical
degradation and can thus be used in applications such as
bioseparation, genomic DNA isolation, or to control the
drug release for several hours to days or months.
Another area that has attracted the interest of researchers
and doctors alike is the ield of stem cell treatment. Many
eforts aremade in order to personalize treatments by admin-
istering stem cells or geneticallymodiied cells.herefore, it is
of great importance to trace the transplanted or injected cells
and to assess their engrating eiciency and functional ability.
For this purpose, SPIONs are being considered as potential
candidates [3, 22].
Although the biocompatibility of iron oxide nanoparti-
cles has been demonstrated, previous studies showing that
once the nanoparticles come in contact with a biological
medium, their surface becomes covered with diferent types
of proteins [7, 23], some SPIONs with core sizes between 3
and 6 nm, coated with dextran, being approved for MRI in
patients [3, 24, 25], their biological activity can increase,
causing potential toxic interactions [26]. It has been estab-
lished that exposure to nanoparticles by people working in
automobile, aerospace, or paint industries [27–32] can lead to
major health problems, including neurotoxicity [7]. In this
context, further studies are needed in order to establish the
efects on the human body by inhaled nanoparticles.
he goal of this study was to prepare iron oxide-silica
nanoparticles from amixture of ferrous chloride tetrahydrate
and ferric chloride hexahydrate dropped into a silica xerogel
composite. he structure and morphology of the synthesized
maghemite nanoparticles into the silica xerogel were analysed
by X-ray difraction (XRD)measurements, scanning electron
microscopy (SEM) equipped with an energy dispersive X-ray
(EDAX) spectrometer, and transmission electronmicroscopy
(TEM). he biocompatibility of iron oxide nanoparticles
embedded in a silica matrix was assessed by cell viability and
cytoskeleton analysis. he biocompatibility of the iron oxide
nanoparticles was evaluated using in vitro and in vivo assays,
consisting in the quantiication of HepG2 cells viability. On
the other hand, histological evaluation of the efect caused by
the obtained nanoparticles on the lungs of male Brown Nor-
way rats ater a single intratracheal instillation of a solution
containing various concentrations of IOSi-NPs was per-
formed in order to clarify the controversial toxicity of these
nanoparticles.
2. Materials and Methods
2.1. Materials. Ferrous chloride tetrahydrate (FeCl2⋅4H2O),
ferric chloride hexahydrate (FeCl3⋅6H2O), chlorhidric acid
(HCl), ethanol, and tetraethylorthosilicate (TEOS) with
99.999% purity were purchased from Sigma-Aldrich and lead
nitrate [Pb(NO3)2] with 99.5% purity was purchased from
Merck.
2.2. Synthesis of Iron Oxide Nanoparticles in Silica Matrix.
hemixture of ferrous chloride tetrahydrate (FeCl2⋅4H2O) in
2M HCl and ferric chloride hexahydrate (FeCl3⋅6H2O) with
the ratio Fe2+/Fe3+ = 1/2 was dropped into a silica xerogel
composite under vigorous stirring for about 1 hour.he start-
ing solution of silica xerogel composite was prepared by mix-
ing tetraethylorthosilicate, water, and ethanol [33]. he water
to TEOS and ethanol to TEOS mole ratios were 11.67 : 1 and
4 : 1.he gel was formed at room temperature under vigorous
stirring. he formed gel based on iron oxide and silica was
dried at room temperature. he inal product was ground to
form a ine powder.he obtained nanocomposite powderwas
then heat treated at 400∘C in an oven, for 24 hours (iron oxide
silica nanoparticles, IOSi-NPs).
2.3. Characterization. he X-ray difraction measurements
were recorded using a Bruker D8 Advance difractometer,
with nickel iltered CuK� (�= 1.5418 A˚) radiation and a high
eiciency one-dimensional detector (LynxEye type) operated
in integration mode. he difraction patterns were collected
in the 2� range 20∘–70∘, with a step of 0.02∘ and 34 s
measuring time per step.
Transmission electron microscopy (TEM) studies were
carried out using a FEI Tecnai 12 equipped with a low dose
digital camera from Gatan. he specimen for TEM imaging
was prepared by ultramicrotomy in order to obtain thin
sections of about 60 nm. he powder was embedded in an
epoxy resin (polaron 612) before microtomy.he particle size
was measured by the SZ-100 Nanoparticle Analyzer (Horiba)
using dynamic light scattering (DLS). he signal obtained
from the scattered light is fed into a multichannel correlator
that generates a function used to determine the translational
difusion coeicient of the particles analysed. he Stokes-
Einstein equation is then used to calculate the particle size.
Scanning electron microscopy (SEM) study was performed
with a FEI Quanta Inspect F scanning electron microscope
equipped with an energy dispersive X-ray attachment. he
magnetic properties of the samples were measured using a
superconducting quantum interference device (MPMS mag-
netometer) at room temperature.
2.4. Cell Cultures and Conditions. he hFOB 1.19 osteoblasts
cells line and theHepG2 cells were purchased fromAmerican
Type Culture Collection (ATCC CCL-121, Rockville, MD,
USA). he cells were routinely maintained in Dulbecco’s
modiied Eagle’s medium (Sigma-Aldrich) supplemented
with 10% fetal bovine serum (Sigma-Aldrich) and 1% antibi-
otic antimycotic solution (including 10,000 units penicillin,
10mg streptomycin, and 25 �g amphotericin B per mL,
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Sigma-Aldrich) at 37∘C in a humidiied atmosphere of 5%
CO2. he cultured cells were loaded on iron oxide-silica
nanocomposite discs at a seeding density of 5 × 104 cells/cm2
in 24-well plates. Cells cultured in 24-well plates at the same
seeding density were used as control.
2.5. In Vitro Cytotoxicity Assay. he viability of the cells was
determined by the tetrazolium salt test [32]. he medium
from each well was removed by aspiration, the cells were
washed with 200�L phosphate bufer solution (PBS)/well,
and then 50�L (1mg/mL) of 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) solution was added
on each well. Ater 2 hours of incubation, the MTT solution
from each well was removed by aspiration. A volume of 50 �L
isopropanol was added and the plate was shaken to dissolve
the formazan crystals. he optical density at 595 nm, for each
well, was then determined using a Tecan multiplate reader
(Tecan GENios, Gro¨dic, Germany).he absorbance from the
wells of cells cultured in the absence of ceramic discs was used
as the 100% viability value.
2.6. Analysis of the Actin Cytoskeleton. he HepG2 cells
were cultured in Dulbecco’s Modiied Eagle’s Medium
(DMEM) supplemented with 10% fetal bovine serum and
100U/100 �g/mL penicillin/streptomycin [34] (purchased
from Invitrogen Co. (Carlsbad, CA)). Ater 24 hours of treat-
ment, the medium was removed and the cells were ixed in
4% paraformaldehyde for 20 minutes at a temperature of 4∘C
andpermeabilizedwith 0.5%TritonX-100 for 1 hour.he cells
were washed with PBS ive times. Ater being washed, the
cells were incubated for 45min in PBS containing FITC-
phalloidin (20�g/mL, Sigma-Aldrich, St. Louis, MO). he
nuclei of cells were counterstained with DAPI-4�-6-diamino-
2-phenylindole (2�g/mL) for 3min and rinsed with PBS.
Mounted slides were visualized and photographed using a
luorescence microscope (Olympus BX51).
2.7. Animals. Male Brown Norway rats (weighing ∼300±
10 g) were purchased from the National Institute of Research
and Development for Microbiology and Immunology “Can-
tacuzino,” Bucharest.he rats were housed in an environment
controlled for temperature (22± 2∘C), light (12 h light/dark
cycles), and humidity (60± 10%). he animals were main-
tained under speciic pathogen-free conditions in accordance
with NIH Guide for the Care and Use of laboratory Animals.
2.8. Intratracheal Instillation. Ater acclimatization for one
week, the rats were randomly divided into four groups (� = 4
per group) to receive vehicle control (saline, 0.9% NaCl,
0.3mL) or instillation of a solution containing 0.5, 2.5, or
5mg/kg IOSi-NPs. he rats were anesthetized with sodium
methohexital (35mg/kg, intraperitoneally) and placed on
an inclined restraint board before instillation with saline
suspension or IOSi-NPs. he IOSi-NPs were suspended in
physiological saline solution. Before intratracheal instillation,
the IOSi-NPs suspension was ultrasonicated for 30min. he
instillation was performed using a nonsurgical intratracheal
instillation method [35] adapted from Hatch et al. [36]. he
rats were anesthetized by ether. According to Bai et al. [35],
a ball tripped needle was maneuvered through the epiglottis,
aterwhich contactwith the tracheal rings provides conirma-
tion that the needle is, in fact, within the trachea. Aterwards,
an injector with 100 �L physiological saline or IOSi-NPs
suspension was inserted into the ball tripped needle. To allow
the luid to drain into the respiratory tree, ater the physio-
logical saline or IOSi-NPs suspension gently instilled into the
trachea, the animal wasmaintained in an upright position for
5min. he rats were euthanized and sacriiced ater 24 h and
one week from the instillation, according to the Guide for
the Care and Use of Laboratory Animals. All animals were
humanely treated and were monitored for any potential
sufering.
2.9. Histological Examination. Histopathology analysis was
performed in Floreasca Emergency Hospital, Bucharest,
Romania.he lungs derived from the rats in the control group
and the treated groups were ixed with 10% neutral bufered
formalin and processed using routine histological techniques.
Ater parain embedding, 3 �m sections were cut and stained
with hematoxylin and eosin (H and E) for histopathologic
evaluation.he morphological changes were observed under
the microscope [37].
3. Results and Discussions
he IOSi-NPs have been widely used for environmental, bio-
logical, andmedical applications but their potential toxicity at
nanometric scale provides a growing concern about the risk
factor for human health. In order to assess the risks of IOSi-
NPs, the objective of this study was to evaluate and compare
the pulmonary responses induced in rats ater intratracheal
instillation of suspensions containing various concentrations
of IOSi-NPs.
Before carrying out the study on evaluating and compar-
ing pulmonary responses induced in rats ater intratracheal
instillation of suspensions containing various concentrations
of IOSi-NPs, characterization of the synthesized ultraine
IOSi-NPs particles was performed using XRD analysis,
EDAX analysis, scanning electronmicroscopy, and transmis-
sion electron microscopy.
Good pattern it has been achieved by the Rietveld
method using MAUD (material analysis using difraction)
[38]. he XRD analysis of iron oxide-silica nanocomposite
Rietveld reinement of X-ray difraction patterns revealed a
phasemixture of maghemite and amorphous silica.he com-
parison between the experimental and calculated data
obtained with the joint Rietveld reinement of the sample is
presented in Figure 1.
he experimental data in blue and the calculated data are
represented by a grey line. Vertical lines represent the posi-
tions of difraction lines of maghemite and amorphous silica.
he line below the grey plot is the diference proile. It resulted
in that each sample is constituted of spherical nanocrystal-
lites. he difraction peak at about 2� = 23 is related to
amorphous silica. Another difraction peak corresponding to
the Miller indices value (hkl) of (220), (311), (400), (422),
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Figure 1: Experimental (blue), calculated (solid line gray), and
diference plot (lover line) of �-Fe2O3 and silica.
(511), and (440) agrees with the cubic structure of maghemite
in Fd3m space group (ICSD-PDF no. 79196) with a lattice
parameter of 8.35 A˚. he XRD showed a slight broadening
of the difraction lines which can be interpreted in terms of
small sized crystallites [39]. he calculated particle size of
maghemite silica nanocomposites was estimated at around
12.5 nm. Based on the XRD data reinement, the formation
of single-phase spinel cubic structure belonging to the Fd3m
space group has been conirmed.he progress of the Rietveld
reinement for the sample is monitored by a number of
agreement parameterssuch as the weighted proile �wp index
and the “goodness of it” (�) index which is the ratio of �wp
over the statistically expected �exp.
On the other hand, in theRietveldmethod,�Bragg is useful
because it depends on the it of the structural parameters and
not on the proile parameters. he inal � factors [40]
obtained from the analysis of the iron oxide-silica nanocom-
posites were given by �wp = 1.0058 (%) and �exp = 0.9530
(%). he resulting Bragg �-factor and chi squared (�2) were
0.58 and 1.1138, respectively. heoretical values of the �
factors obtained for maghemite-silica nanocomposites are in
good agreement with the theory of Toby [41].
Information about the size and typical shape of the IOSi-
NPs obtained ater heat treatment at 400∘C of the obtained
initial nanocomposites powder based iron oxide and silica
was provided from SEM analysis. SEM image of maghemite-
silica nanocomposites showed very small particle sizes and
uniform spherical shapes (Figure 2(a)). EDAX spectrum
and elemental maps (Figure 2(b)) of Fe, O, and Si for the
maghemite-silica nanocomposites are also presented. he
uniform distributions of Fe, O, and Si could be observed.
he morphological investigation of iron oxide-silica
nanoparticles was performed using transmission electron
microscopy (TEM). Figure 3 shows the TEM image of IOSi-
NPs, the selected area electron difraction (SAED), and
size distribution of the particles. Details observed at high
magniication (180000x) show monodisperse IOSi-NPs with
spherical shape and a monomodal particle size distribution.
he average size deduced from the particle size distribution is
13.7 ± 0.6 nm,which is in good agreementwithXRDanalysis.
Dynamic light scattering known as Quasi-Elastic Light
Scattering was used to determine the size distribution proile
of small maghemite-silica particles in suspension. he mag-
hemite-silica nanoparticles observed by DLS are monodis-
perse in water (Figure 4).he size of IOSi-NPs deduced from
TEM images is consistent with the DLS size proiles (14 nm).
Magneticmeasurements of the iron oxide-silica nanopar-
ticles were carried out using vibrating sample magnetometer
(VSM). Magnetization curves (M-H loop) for the IOSi-NPs
obtained ater heat treatment at 400∘C measured at room
temperature are presented in Figure 5.
According to Dormann et al. [42], iron oxide-silica
nanoparticles keep the superparamagnetic characteristic of
the iron oxide nanoparticles. From hysteresis measurements,
the zero coercivity ields of IOSi-NPs can be considered equal
to 0Oe at 300K. he very little value of coercivity ields
observed in Figure 5(b) can be attributed to the fact that iron
oxide nanoparticles in silica matrix do not have the ability to
rotate freely. In agreement with Im et al. [43], the magnetic
domain sizes of iron oxide nanoparticles in silica matrix can
be easily over the limit of superparamagnetism. According
to previous studies [43, 44], the silica colloids at room
temperature exhibit a very small coercivity. On the other
hand, the value of saturation magnetizations, Ms, was about
22.29 emu/g. In previous studies, Pareta et al. [45] have
attributed the low saturation magnetization of iron oxide in
silica matrix to the diamagnetic contribution of the SiO2
shells covering the iron oxide nanoparticles, thus weakening
the magnetic moment for iron oxide/SiO2 nanoparticles due
to the occurrence of thicker shells.
In order to quantitatively evaluate the hFOB 1.19
osteoblast cell viability, we performed MTT assay (Figure 6).
he cell viability of hFOB 1.19 osteoblasts cells in the presence
of various concentrations of IOSi-NPs (concentrations from
25 to 100 �g/mL) ater 24 h indicated that osteoblast viability
was similar in the presence of IOSi-NPs compared to the
control, as shown in Figure 6(a). Ater exposure to increasing
concentrations from 25 to 100 �g/mL of IOSi-NPs for 48 h,
the cell viability of hFOB 1.19 osteoblasts cells is not inlu-
enced by the presence of IOSi-NPs (Figure 6(b)).
In the present study, ater 24 h and 48 h from exposure
with IOSi-NPs, there could not be observed higher values
of cell viability in the presence of IOSi-NPs (concentrations
from 25 to 100 �g/mL) compared to the control. It was thus
proved that the IOSi-NPs remain dispersed in cell cul-
ture, keeping bioactivity for all concentrations from 25 to
100 �g/mL [45]. he cytotoxicity test by MTT assay, using
hFOB 1.19 osteoblasts cells, has indicated that the studied
IOSi-NPs were nontoxic to the cells.
On the other hand, we tested the cell viability of HepG2
cells in the presence of various concentrations of IOSi-NPs
and the expression of F-actin in HepG2 cells adhered on
IOSi-NPs nanoparticles. Ater exposure to increasing con-
centrations from 25 to 100 �g/mL of IOSi-NPs for 24 h and
48 h, the cell viability of HepG2 cells was measured using
MTT assay (Figure 7). In order to investigate the cell viability,
it is relevant to note that in all the studies, the cells are not
inluenced by the presence of IOSi-NPs, preserving a good
morphology adhesion. When the concentration of IOSi-
Nps increased, the cell variability decreased from 100%
(25 �g/mL) to 90% (100 �g/mL) ater 24 h. Ater 48 h, the cell
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Figure 2: SEM micrographs (a) and elemental maps of maghemite-silica nanocomposite.
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Figure 3: TEMmicrograph (high magniication at 180000x) showing the spherical IOSi-NPs, selected area electron difraction (SAED), and
size distribution.
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Figure 4: DLS showing mean average size of maghemite-silica nanoparticles.
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Figure 5: M-H curves of IOSi-NPs at room temperature in full scale (a) and in extended scale (b).
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Figure 6: Cell viability data assessed by a MTT assay for hFOB 1.19 osteoblast cells incubated for 24 h (a) and 48 h (b) with the IOSi-NPs at
various concentrations (25, 50, 75, and 100�g/mL).
variability decreased to 92% when the IOSi-NPs concentra-
tion is equal to 100�g/mL [46]. Furthermore, ater 48 hours
of exposure with IOSi-NPs, we observed a tendency of linear
increase of viability and proliferation (Figure 7).
his efect might be due to cells adaptation at interaction
with IOSi-NPs nanocomposites. According to Weichsel et al.
[47], the modeling and spatial organization of the actin cyto-
skeleton is a very active and increasingly sophisticated
research.
he functions of the actin cytoskeleton are to mediate a
variety of essential biological functions in all eukaryotic cells,
including intra- and extracellular movement and structural
support. In order to perform these functions, the organiza-
tion of the actin cytoskeleton must be tightly regulated both
temporally and spatially [48]. According to previous studies
on the size efect on cell uptake in well-suspended, uniform
mesoporous silica nanoparticles [49], facile synthesis of
monodispersed mesoporous silica nanoparticles with ultra
large pores and their application in gene delivery [50] and
silica-based complex nanorattles as multifunctional carrier
for anticancer drug [51] showed that for intracellular drug
delivery and eicient therapy, an eicient cellular internaliza-
tion of nanoparticles is necessary.
For detection of F-actin, the major constituent of micro-
ilaments (green), the cells were ixed and stained with
FITC phalloidin (Figure 8). he cells were stained with 4,6-
diamidino-2-phenylindole dihydrochloride (DAPI) in order
to visualize cell nuclei.
Ater cells treatment with the IOSi-NPs, there could not
be found any morphological changes with observable frag-
mented nuclei. Moreover, staining of F-actin and nuclear
staining have shown that the assimilation of the nanoparticles
did not have any efect on nuclear morphology nor on the
cytoskeleton of transfected cells.
According to previous studies [52, 53], at this stage, little is
known about the possible interactions of nanomaterials with
biological systems. Development of new nanomaterials may
lead to major health problems induced by frequent exposure
BioMed Research International 7
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Figure 7: Cell viability data assessed by a MTT assay for HepG2 cells incubated for 24 h (a) and 48 h (b) with the IOSi-NPs at various
concentrations (25, 50, 75, and 100�g/mL).
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Figure 9: Light optical image of the lung at 24 h ater intratracheal instillation of IOSi-NPs in rats at various concentrations. he reference
sample is also presented (a). Lung ater 24 hours: control (a), 0.5mg/kg (b), 2.5mg/kg (c), and 5mg/kg (d).
to these airborne nanoparticles. From this point of view, the
potential toxic efects of IOSi-NPs by intratracheal instillation
are discussed. Although it has been shown that the iron
oxide and silica nanoparticles have an excellent potential for
biomedical applications, there is not an understanding of
their potential systemic toxicity. According to the previous
studies of Drobne [54] and Seaton [55], the particular
nanoscale properties are likely to afect not only the chemistry
and physics but also their behaviour in biological systems.
he toxicity evaluation ater 24 h and 7 days from intratra-
cheal instillation of various concentrations of IOSi-NPs in
rats was performed by histopathological analysis (Figures 9–
12). All animals survived the administration of IOSi-NPs on
all the tested concentrations and did not show any sign of
discomfort (lethargy, nausea, vomiting, or diarrhea) during
the whole duration of the experiment. he histopathological
assessment of the selected tissues such as lung and liver was
conducted.
he toxicity evaluation of the lung ater 24 h from
intratracheal instillation of various concentrations of IOSi-
NPs in rats was observed by histopathological investiga-
tions (Figure 9). Ater 24 h from intratracheal instillation,
the rats showed particle-induced modiications that were
dependent on the concentrations used. Ater 24 h from the
intratracheal instillationwith 0.5mg/kg of IOSi-NPs, the lung
parenchyma of the rats showed preserved alveolar architec-
turewith raremacrophages in the alveolar septa.We could see
that the pathological micrographs of lung in rats ater the
intratracheal instillation with 0.5mg/kg dose of IOSi-NPs
(Figure 9(b)) show that the lung has preserved the architec-
ture of the control specimen (Figure 9(a)), with no signiicant
diferences. Ater the intratracheal instillation of the rats
with a 2.5mg/kg (Figure 9(c)) dose of IOSi-NPs, the lung
parenchyma of the rats showed preserved alveolar architec-
ture with rare macrophages in the alveolar septa, discreet
anisokaryosis, and anisochromia of type II pneumocytes
with rare nucleoli. Lung parenchyma of the specimen ater
intratracheal instillation of IOSi-NPs in rats at concentration
of 5mg/kg (Figure 9(d)) showed preserved alveolar archi-
tecture with macrophages in the alveolar septa, discreet
anisokaryosis, and anisochromia of type II pneumocytes,
with chromocenters and nucleoli. In the lung parenchyma,
focal ectatic capillaries were also observed in the alveolar
septa.
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Figure 10: Light optical image of the lung at 7 days ater intratracheal instillation of IOSi-NPs in rats at various concentrations.he reference
sample is also presented (a). Lung ater 7 days: control (a), 0.5mg/kg (b), 2.5mg/kg (c), and 5mg/kg (d).
However, the efect of IOSi-NPS on lungs, even for
concentration of 5mg/kg, was markedly reduced ater 7 days
of treatment. Ater 7 days from intratracheal instillation of the
rats with 5mg/kg IOSi-NPs (Figure 10(d)), we observed that
the lung parenchyma show preserved alveolar architecture
with rare macrophages, discreet anisokaryosis, and anisoch-
romia of type II pneumocytes, with rare chromocenters and
nucleoli (Figure 10(d)). On the other hand, the pathological
micrographs of lungs in rats ater the intratracheal instillation
with 0.5mg/kg and 2.5mg/kg dose of IOSi-NPs (Figures
10(b)-10(c)) show that the lung has preserved the architecture
of the control specimen (Figure 10(a)) with no signiicant
diferences.
According to the literature [56], the liver is the irst
organ exposed to nanoparticles that are capable to enter into
the circulation ater intratracheal instillation because it is
the major organ for biotransformation of toxins. he liver
examination ater intratracheal instillation of the rats with
various concentrations of IOSi-NPs (Figure 11) indicates that
the liver has preserved the architecture of the control spec-
imen (Figure 11(a)) with no signiicant diferences even for
values of 5mg/kg.
Ater microscopic examination of the liver and spleen
24 h from intratracheal instillation of IOSi-NPs in rats, we can
see that none of the organs other than the lung revealed any
related toxic response, in good agreement with previous
studies [57].
Previous studies [58, 59] suggested that smaller sized
nanoparticles could initiate lung injury such as the inlam-
mation in lung, which induced endothelial-epithelial damage
and subsequent iniltrated leukocytes that allowed large
amounts of smaller nanoparticles to pass easily into circula-
tion.Moreover, in the lung injury, the size and concentrations
of nanoparticles play a major role.
Iron oxide nanoparticles were developed rapidly and
because of their superparamagnetic characteristics, they are
of considerable interest for potential applications in biology
and medicine, magnetic target drug delivering, and environ-
mental catalysis. According to previous studies of Wu et al.
[60], the surface functionalizedmagnetic iron oxide nanopar-
ticles are a kind of novel functional material, which has been
widely used in the biotechnology and catalysis. he present
studies enrol to investigate the interaction of these nanopar-
ticles with biological systems. he aim of this study was to
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Figure 11: Light optical image of the liver at 24 h ater intratracheal instillation of IOSi-NPs in rats at various concentrations. he reference
sample is also presented (a). Liver ater 24 hours: control (a), 0.5mg/kg (b), 2.5mg/kg (c), and 5mg/kg (d).
evaluate the potentially toxic efects of IOSi-NPs on the lungs,
spleen, and liver of rats ater being exposed for 24 h and
7 days, respectively, to a single intratracheal instillation of
solutions containing concentrations of 0.5, 2.5, or 5mg/kg.
Consistent with other reports examining various materi-
als like CeO2 [61, 62], titanium dioxide [63], silica [64], and
copper [65] nanoparticles, our data suggest that IOSi-NPs are
not capable of translocating from the lungs to the liver via the
circulatory system at all the tested concentrations. he his-
topathological appearance of the liver ater intratracheal
instillation of IOSi-NPs in rats shows that the diferent
pathological alterations such as enlargement of hepatocytes,
hydropic degeneration of hepatocytes, nuclear enlargement,
and dilatation of the sinusoids were not observed at concen-
trations of 0.5, 2.5, and 5mg/kg.
4. Conclusions
he purpose of our research focuses on the development of
various strategies of synthesis and control of the structure
and magnetic properties of surface functionalized iron oxide
nanoparticles and their corresponding applications. Iron
oxide nanoparticles were encapsulated in a silica matrix.
Silica coated magnetic nanoparticles have been previously
synthesized by adding into a silica xerogel composite themix-
ture of ferrous chloride tetrahydrate and ferric chloride hex-
ahydrate. A systematic study of the formation of iron oxide
coated with silica was made. he IOSi-NPs characterized by
various techniques were found to have a narrow size distribu-
tion with an average size deduced from TEM measurements
of around 13.7± 0.6 nm in good agreement with the size
deduced from the XRD analysis that was estimated at around
12.5 nm.
In terms of the viability, it can be noted that in all the
studies, the cell viability was not inluenced by the presence
of IOSi-NPs, preserving a good morphology adhesion.
Ater microscopic examination of the lungs, liver, and
spleen ater 24 h from intratracheal instillation with doses of
0.5mg/kg, 2.5mg/kg, and 5mg/kg IOSi-NPs in rats, we could
see that none of the organs other than the lung revealed any
toxic response. On the other hand, the efect of IOSi-NPS on
lung, even for a concentration of 5mg/kg, was markedly
reduced ater 7 days of treatment.
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Figure 12: Light optical image of the spleen at 24 h ater intratracheal instillation of IOSi-NPs in rats at various concentrations.he reference
sample is also presented (a). Spleen ater 24 hours: control (a), 0.5mg/kg (b), 2.5mg/kg (c), and 5mg/kg (d).
In conclusion, we demonstrated that intratracheal expo-
surewith doses containing 0.5mg/kg, 2.5mg/kg, and 5mg/kg
IOSi-NPs did not initiate acute lung injury and that the
synthesized nanoparticles with sizes around 12.5 nm are not
able to enter into the circulatory system.
In this study we tried to answer some questions of the
currently pressing problems regarding the toxicity of nano-
particles and their behaviour in vitro and in vivo. For a better
understanding of the behaviour of these nanoparticles on
healthmore complex studies will have to be carried out in the
future on toxicity induced ater intratracheal instillation of
ine and ultraine particles.
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